Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma By Ogkologos - July 9, 2026 36 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SUCCESSOR-2 study Source RELATED ARTICLESMORE FROM AUTHOR Benefit of Adjuvant Chemotherapy in Patients with ctDNA-positive Resected Stage II Colon Cancer FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy for the Maintenance Treatment of HR-positive, HER2-positive LA/MBC Peptide Receptor Radionuclide Therapy [177Lu]Lu-Edotreotide Prolongs PFS in Patients with Advanced, Progressive, Somatostatin Receptor-Positive GEP NETs MOST POPULAR Cancer services during COVID-19: 40,000 fewer people starting treatment February 2, 2021 How to Clean Your Home When Caring for Someone With Cancer October 7, 2020 Your questions on our research strategy March 29, 2022 Breast Cancer Patient Who Continued Teaching Throughout Her Treatment Wins Teacher... February 9, 2021 Load more HOT NEWS Virtual Mind–Body Fitness Classes Show Unexpected Benefit in People with Cancer FDA Grants Accelerated Approval to fam-Trastuzumab Deruxtecan-nxki for HER2-Mutated NSCLC Could a Vaccine Prevent Colorectal Cancer in People with Lynch Syndrome? FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma
